GeneDx Holdings (WGS) Financial Statements & Analysis

GeneDx Holdings (WGS) Income Statement

GeneDx Holdings reported revenue of $427.54M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 40.0% from $305.45M a year earlier. GeneDx Holdings posted a net loss of $21.02M, compared with a net loss of $52.29M a year earlier. Gross margin was 69.7% and operating margin -3.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $114.44M, up 11.4% from the same quarter a year earlier.

GeneDx Holdings Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

GeneDx Holdings Corp. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	427.54	305.45	202.57	234.69	212.20	179.32
Cost of Revenue	129.37	111.00	112.56	261.44	228.80	175.30
Gross Profit	298.17	194.40	90.01	-26.75	-16.60	4.03
Operating Expenses
Research & Development	72.03	45.72	58.27	86.20	105.16	72.70
Selling, General & Administrative	239.22	171.89	199.98	338.24	318.73	163.93
Operating Expenses	311.25	217.61	260.20	640.90	429.55	246.02
Operating Income	-13.08	-23.21	-170.19	-667.65	-446.15	-241.99
Other Income/Expense
Interest Income	0.00	0.00	1.11	2.54	0.08	0.51
Interest Expense	-2.54	-3.03	0.00	3.21	2.84	2.47
Other Income/Expense	-5.52	-29.42	-7.61	69.62	203.52	0.65
Income
Income Before Tax	-21.14	-52.63	-176.69	-598.03	-245.39	-241.34
Income Tax Expense	-0.12	-0.34	-0.93	-49.05	0.00	0.00
Net Income	-21.02	-52.29	-175.77	-548.98	-245.39	-241.34
Net Income - Continuous Operations	-21.02	-52.29	-175.77	-548.98	-245.39	-241.34
Net Income - Discontinued Operations	-	-	-	-	-	-
EBITDA	12.15	-2.11	-136.46	-398.20	-220.75	-227.13
EBIT	-13.08	-23.16	-170.19	-457.51	-242.56	-
Depreciation & Amortization	25.22	21.05	33.73	59.31	21.81	11.73
Earnings Per Share
Basic EPS	-1.00	-2.00	-7.00	-54.00	-75.00	-33.00
Diluted EPS	-1.00	-2.00	-7.00	-54.00	-75.00	-147.00
Basic Shares Outstanding	28.64	26.89	24.31	10.24	3.28	5.63
Diluted Shares Outstanding	28.64	26.89	24.31	10.24	3.28	5.63

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About GeneDx Holdings Financial Statements

What was GeneDx Holdings's revenue in fiscal 2025?

GeneDx Holdings reported revenue of $427.54M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 40.0% from $305.45M a year earlier.

Is GeneDx Holdings profitable?

No. GeneDx Holdings reported a net loss of $21.02M in fiscal 2025. In fiscal 2024 it lost $52.29M.

What is GeneDx Holdings's operating margin?

GeneDx Holdings's operating income was −$13.08M on revenue of $427.54M in fiscal 2025, an operating margin of -3.1%, compared with -7.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition